All In Biotech

Drug Trial Radar · NCT05480761

7-Day Trial of Sucraid for Alleviating CSID Symptoms in Subjects With Low, Moderate, and Normal Sucrase Levels

Evaluation of a 7-Day Therapeutic Trial Dose of Commercial Sucraid® (Sacrosidase) Oral Solution for Alleviating Congenital Sucrase-Isomaltase Deficiency (CSID) Symptoms in Pediatric Subjects With Low, Moderate, and Normal Sucrase Levels

Last checked: Nov 20, 2026Latest source record: Mar 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

312

Actual

Start

Aug 1, 2022

Primary completion

Sep 18, 2024

Study completion Sep 18, 2024

Sponsor

Lead sponsor
QOL Medical, LLCIndustry
Sponsor type
Industry
First posted
Jul 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 4, U.S. only, multi-center study using a 7-day therapeutic response dose (TRD) of commercial Sucraid® to assess the response of treatment in 1100 symptomatic pediatric (6 months to 17 years old) subjects with low, moderate, and normal sucrase activity determined by a disaccharidase assay via EGD within 1 year of the Screening Visit. This study will also explore the relationship between known genetic CSID mutations and sucrase activities via (EGD) disaccharidase assay (low, moderate, and normal).

Conditions

  • Congenital Sucrase-Isomaltase Deficiency
  • CSID
  • Sucrase Isomaltase Deficiency

Interventions

  • Sucraid (sacrosidase) Oral Solution 8500 IU/mLBiological

    Sucraid is a pale yellow to colorless, clear solution of glycerol, water, and citric acid, with a pleasant, sweet taste. Each milliliter of Sucraid contains 8,500 IU of the enzyme sacrosidase, the active ingredient.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effects of Sucraid® treatment on gastrointestinal symptoms in subjects with low, moderate, and normal disaccharidase assay sucrase levels from an esophagogastroduodenoscopy (EGD).Time frame: Post 7-day run-in period plus 7-day treatment period.

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Children's Hospital Los Angeles

    Los Angeles, California

  • UCSF Benioff Children's Hospital Oakland

    Oakland, California

  • Kidz Medical

    Coral Gables, Florida

  • Orlando Health

    Orlando, Florida

  • Children's Healthcare of Atlanta

    Atlanta, Georgia

  • Center for Digestive Health Care, LLC

    Atlanta, Georgia

  • University of Maryland Baltimore

    Baltimore, Maryland

  • Johns Hopkins University

    Baltimore, Maryland

  • GI Associates

    Flowood, Mississippi

  • Happy Tummies

    Flowood, Mississippi

  • Children's Mercy Hospital

    Kansas City, Missouri

  • Atlantic Health System

    Morristown, New Jersey

  • WNY Pediatric Gastroenterology

    Buffalo, New York

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Measurable Outcomes Research

    Oklahoma City, Oklahoma

  • Prisma Health

    Greenville, South Carolina

  • GI For Kids, PLLC

    Knoxville, Tennessee

  • Newco 3A Research,LLC DBA 3A Research

    El Paso, Texas

  • Pediatric GI of El Paso, LLC

    El Paso, Texas

  • McGovern Medical School of UT Health

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.